公开(公告)号：US20180280469A1

公开(公告)日：2018-10-04

申请号：US15881123

申请日：2018-01-26

申请人： Ferring B.V.

发明人： Anders NILSSON ,  Hans LINDNER ,  Jørgen WITTENDORFF

IPC分类号： A61K38/11 ,  A61K47/42 ,  A61K47/26 ,  A61K47/12 ,  A61K38/12 ,  A61K38/08

CPC分类号： A61K38/11 ,  A61K9/0056 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2063 ,  A61K9/2095 ,  A61K38/08 ,  A61K38/12 ,  A61K47/12 ,  A61K47/26 ,  A61K47/42

摘要： Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.

公开(公告)号：US20170112895A1

公开(公告)日：2017-04-27

申请号：US15333503

申请日：2016-10-25

申请人： Ferring B.V.

发明人： Anders NILSSON ,  Hans LINDNER ,  Jørgen WITTENDORFF

IPC分类号： A61K38/11 ,  A61K47/12 ,  A61K47/26 ,  A61K47/42 ,  A61K9/00

CPC分类号： A61K38/11 ,  A61K9/0056 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2063 ,  A61K9/2095 ,  A61K38/08 ,  A61K38/12 ,  A61K47/12 ,  A61K47/26 ,  A61K47/42

摘要： Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.

公开(公告)号：US20160175246A1

公开(公告)日：2016-06-23

申请号：US14947261

申请日：2015-11-20

申请人： Ferring B.V.

发明人： Anders NILSSON ,  Hans LINDNER ,  Jørgen WITTENDORFF

IPC分类号： A61K9/00 ,  A61K47/42 ,  A61K38/12

CPC分类号： A61K38/11 ,  A61K9/0056 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2063 ,  A61K9/2095 ,  A61K38/08 ,  A61K38/12 ,  A61K47/12 ,  A61K47/26 ,  A61K47/42

摘要： Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.